274 related articles for article (PubMed ID: 6355722)
1. Studies on dapsone-resistant Mycobacterium leprae in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 2. A progress report.
Almeida JG; Christian M; Chacko CJ; Taylor PM; Fritschi EP
Lepr Rev; 1983 Sep; 54(3):185-91. PubMed ID: 6355722
[No Abstract] [Full Text] [Related]
2. Dapsone-resistant leprosy in Burundi.
Bourland J; Van Loo L; Pattyn SR
Lepr Rev; 1983 Sep; 54(3):239-42. PubMed ID: 6355726
[No Abstract] [Full Text] [Related]
3. Secondary dapsone-resistant leprosy in Shanghai Municipality.
Ji BH; Chen JK; Zhang JL; Hou YH; Ni GX; Zhang RB
Lepr Rev; 1983 Sep; 54(3):197-202. PubMed ID: 6355724
[No Abstract] [Full Text] [Related]
4. Dapsone-resistant leprosy and its implications for leprosy control programmes.
Pearson JM; Cap JA; Haile GS; Rees RJ
Lepr Rev; 1977 Jun; 48(2):83-94. PubMed ID: 331000
[No Abstract] [Full Text] [Related]
5. Dapsone-resistant leprosy in Jakarta: a preliminary report.
Utji R; Kosasih A; Santoso AU
Lepr Rev; 1983 Sep; 54(3):193-5. PubMed ID: 6355723
[No Abstract] [Full Text] [Related]
6. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.
Levy L; Shepard CC; Fasal P
Am J Trop Med Hyg; 1972 May; 21(3):315-21. PubMed ID: 4554496
[No Abstract] [Full Text] [Related]
7. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
Browne SG
Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
[No Abstract] [Full Text] [Related]
8. Dapsone-resistant leprosy in a population of Bamako (Mali).
Baquillon G; Ferracci C; Saint Andre P; Pattyn SR
Lepr Rev; 1980 Dec; 51(4):315-9. PubMed ID: 7012500
[No Abstract] [Full Text] [Related]
9. Primary dapsone-resistant leprosy.
Pearson JM; Haile GS; Rees RJ
Lepr Rev; 1977 Jun; 48(2):129-32. PubMed ID: 330999
[No Abstract] [Full Text] [Related]
10. Prevalence of secondary dapsone-resistant leprosy in Upper Volta.
Pattyn SR; Yada A; Sansarricq H; van Loo L
Lepr Rev; 1984 Dec; 55(4):361-7. PubMed ID: 6396476
[No Abstract] [Full Text] [Related]
11. Combined clofazimine- and dapsone-resistant leprosy. A case report.
Kar HK; Bhatia VN; Harikrishnan S
Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345
[TBL] [Abstract][Full Text] [Related]
12. Ulcerating lepromatous leprosy in a patient with dapsone-resistant Mycobacterium leprae.
McDougall AC; Rees RJ
Lepr Rev; 1973 Jun; 44(2):59-64. PubMed ID: 4582180
[No Abstract] [Full Text] [Related]
13. Clinical assessment and management of dapsone-resistant leprosy for the field worker.
Warren G
Lepr Rev; 1977 Jun; 48(2):113-21. PubMed ID: 330996
[No Abstract] [Full Text] [Related]
14. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies.
Rees RJ; Waters MF; Pearson JM; Helmy HS; Laing AB
Int J Lepr Other Mycobact Dis; 1976; 44(1-2):159-69. PubMed ID: 776852
[No Abstract] [Full Text] [Related]
15. Primary dapsone-resistant leprosy in Cebu, Philippines.
Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC
Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the multiplication of dapsone-resistant strains of Mycobacterium leprae in mice. Subcommittee on Clinical Trials of the C hemotherapy of Leprosy (THELEP) Scientific Working Group of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.
Lepr Rev; 1988 Mar; 59(1):5-10. PubMed ID: 3294541
[No Abstract] [Full Text] [Related]
17. The prevalence of dapsone-resistant leprosy in Israel.
Levy L; Rubin GS; Sheskin J
Lepr Rev; 1977 Jun; 48(2):107-12. PubMed ID: 330995
[No Abstract] [Full Text] [Related]
18. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
[No Abstract] [Full Text] [Related]
19. DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results.
Almeida JG; Chacko CJ; Christian M; Taylor PM; Fritschi EP
Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):366-73. PubMed ID: 6685699
[TBL] [Abstract][Full Text] [Related]
20. Does dapsone resistance really matter in the MDT era?
Ji B
Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
